BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 18451221)

  • 1. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
    Ignatiadis M; Kallergi G; Ntoulia M; Perraki M; Apostolaki S; Kafousi M; Chlouverakis G; Stathopoulos E; Lianidou E; Georgoulias V; Mavroudis D
    Clin Cancer Res; 2008 May; 14(9):2593-600. PubMed ID: 18451221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.
    Ignatiadis M; Perraki M; Apostolaki S; Politaki E; Xenidis N; Kafousi M; Stathopoulos E; Lianidou E; Sotiriou C; Georgoulias V; Mavroudis D
    Clin Breast Cancer; 2007 Dec; 7(11):883-9. PubMed ID: 18269779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.
    Apostolaki S; Perraki M; Kallergi G; Kafousi M; Papadopoulos S; Kotsakis A; Pallis A; Xenidis N; Kalmanti L; Kalbakis K; Agelaki S; Kalykaki A; Stournaras C; Stathopoulos E; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2009 Oct; 117(3):525-34. PubMed ID: 19016323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
    Xenidis N; Ignatiadis M; Apostolaki S; Perraki M; Kalbakis K; Agelaki S; Stathopoulos EN; Chlouverakis G; Lianidou E; Kakolyris S; Georgoulias V; Mavroudis D
    J Clin Oncol; 2009 May; 27(13):2177-84. PubMed ID: 19332733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
    Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
    Souglakos J; Vamvakas L; Apostolaki S; Perraki M; Saridaki Z; Kazakou I; Pallis A; Kouroussis C; Androulakis N; Kalbakis K; Millaki G; Mavroudis D; Georgoulias V
    Breast Cancer Res; 2006; 8(4):R36. PubMed ID: 16846533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer.
    Ferrucci PF; Rabascio C; Mazzetta C; Cocorocchio E; Agazzi A; Vanazzi A; Cinieri S; Peccatori FA; Paolucci M; Bertolini F; Martinelli G
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6039-46. PubMed ID: 15447988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes.
    Nakagawa T; Martinez SR; Goto Y; Koyanagi K; Kitago M; Shingai T; Elashoff DA; Ye X; Singer FR; Giuliano AE; Hoon DS
    Clin Cancer Res; 2007 Jul; 13(14):4105-10. PubMed ID: 17634536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR.
    Ntoulia M; Stathopoulou A; Ignatiadis M; Malamos N; Mavroudis D; Georgoulias V; Lianidou ES
    Clin Biochem; 2006 Sep; 39(9):879-87. PubMed ID: 16925986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression.
    Parikh RR; Yang Q; Higgins SA; Haffty BG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):35-42. PubMed ID: 17855007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous detection of multiple mRNA markers CK19, CEA, c-Met, Her2/neu and hMAM with membrane array, an innovative technique with a great potential for breast cancer diagnosis.
    Chen CC; Hou MF; Wang JY; Chang TW; Lai DY; Chen YF; Hung SY; Lin SR
    Cancer Lett; 2006 Aug; 240(2):279-88. PubMed ID: 16289546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer.
    Reinholz MM; Nibbe A; Jonart LM; Kitzmann K; Suman VJ; Ingle JN; Houghton R; Zehentner B; Roche PC; Lingle WL
    Clin Cancer Res; 2005 May; 11(10):3722-32. PubMed ID: 15897569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
    Chen Y; Zou TN; Wu ZP; Zhou YC; Gu YL; Liu X; Jin CG; Wang XC
    Int J Biol Markers; 2010; 25(2):59-68. PubMed ID: 20586026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients.
    Masuda TA; Kataoka A; Ohno S; Murakami S; Mimori K; Utsunomiya T; Inoue H; Tsutsui S; Kinoshita J; Masuda N; Moriyama N; Mori M
    Int J Oncol; 2005 Mar; 26(3):721-30. PubMed ID: 15703829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor cells in breast cancer.
    Ignatiadis M; Georgoulias V; Mavroudis D
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):55-60. PubMed ID: 18197007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.
    Taback B; Chan AD; Kuo CT; Bostick PJ; Wang HJ; Giuliano AE; Hoon DS
    Cancer Res; 2001 Dec; 61(24):8845-50. PubMed ID: 11751407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of suspension array assay to detect marker genes expression of circulating tumor cells for early prediction of breast cancer metastasis].
    Ke F; Wu JM; Yao JE; Bai YJ; Guo AL
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2257-61. PubMed ID: 18001545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
    Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
    Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status.
    Xu Y; Yao L; Li H; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Larsson O; Xie Y
    Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.